Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026 Featuring 767 Cell Therapies in the Clinical Pipeline & 25 Marketed Cell Therapies – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global
Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity
Insight 2026” report has been added to ResearchAndMarkets.com’s
offering.

“Global Cell Therapy Market, Clinical Trials, Therapy Price &
Opportunity Insight 2026” Report Highlights

• Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by
  2026
• Cell Therapy Clinical Trial Insight by Indication, Company & Country
• Global Cell Therapy Clinical Pipeline: 767 Cell Therapies
• Globally Marketed Cell Therapies: 25 Cell Therapies
• Maximum Number of Marketed Cell Therapies In USA: 15 Therapies
• Price & Product Insight By Region/Country
• Regional Analysis of the Cell Therapy Market

In recent years, there has been a steady increase in the interest shown
in the cell therapy segment from big pharmaceutical, biotech and medical
device companies. Earlier, the idea for altering a cell or a gene to
cure or treat disease was considered impossible. But with the ongoing
advancements, it has now become possible in the treatment or cure of a
disease with the help of cell therapy.

Cell therapies are still in the early stages of clinical development and
are expected to evolve in the market with a vast number of opportunities
in the healthcare industry. In order to form a stable base for process
evaluation and development it will be essential to understand the
quality of cell-based products. With an increasing number of cell
therapies and clinical indications being assessed, it is clear that
consideration will be given on how these therapies will be carried out
and subsequently be delivered to the patients on a clinical relevancy
scale.

Currently, there are more than 750 cell-based therapies in the clinical
pipeline. Most of the cell therapies are in Preclinical phase followed
by Phase-I clinical trials. Analysis of the pipeline shows that the
majority of the cell therapy products that are currently under
development are targeted towards treatment of complex disease like
cardiovascular disease, neural disease and cancer. More than 20 cell
therapies are commercially available in the market. However, when it
comes to marketed products, more than half of the products that are
currently available are in the tissue and skin treatment segment such as
Apligraf and Dermigraf.

Few cell therapy products such as Kymriah, Provenge and Yescarta have
emerged as the most promising therapeutics of the decade with excellent
result in treatment of various clinical indications, but the market
remains widely untapped due to the high price tag.

The cell therapy technique finds wide usage in almost all types of
therapeutic areas. However, the majority of the cell therapy research is
currently being done in cancer, Neurological, Cardiovascular and
Inflammatory segments due to their high mortality rate among the global
population. Few cell therapy research is being done in the diabetic
segment too where the aim is to develop an artificial pancreas using
cell therapy which would work just like a natural pancreas.

Cell therapies will also have the potential to replace many risky,
costly and invasive surgeries. For many disease conditions, such as
diabetes, patients are required to take a prescription on a daily basis.
A cell therapy approach will substantially reduce the healthcare costs
of this disease by providing a one-time treatment. In the same way cell
therapy approaches to pain management will also reduce the costs of
opioid-based pain medications. Cell therapy, in combination with the
recent advances in iPS cell generation and CRISPR-Cas 9, also has a
great opportunity in the future.

The path towards the success for cell therapy will consist of a
combination of scenarios that is being imagined for the cure of diseases
and is hoped that these will definitely come true in the near future.
The advantages and risks of current cell therapy practices will improve
translational success and accelerate the clinical development of safe
and efficient cell products in the future.

Key Topics Covered:

1. Overview of Cell Therapy

1.1 Introduction to Cell Therapy

1.2 History & Evolution of Cell Therapy

2. Types of Cell Therapy

2.1 Allogeneic Cell Therapy

2.2 Autologous Cell Therapy

2.3 Human Embryonic Stem Cell Therapy

2.4 Neural Stem Cell Therapy

2.5 Mesenchymal Stem Cell Therapy

2.6 Hematopoietic Stem Cell Transplantation

3. Mechanism of Therapeutic Action in Cell Therapy

4. Manufacturing of Cell Therapies

4.1 Models for Manufacturing Cell Therapies

4.2 Facilities for Good Manufacturing Practice

5. Advantages of Cell Therapy Over Conventional Therapy

5.1 Anti-Aging with Cell Therapy

5.2 Addressing Other Diseases with Cell Therapy

6. Personalized Cell Therapy

6.1 Overview of Personalized Cell Therapy

6.2 Personalized Cell Therapy Using Epigenetic Tools

6.3 Personalized Cell Therapy through Mesenchymal Stem Cells

6.4 Treatment of Parkinson’s Disease through IPSCs

6.5 Case Study: Personalized Cell Therapy for Pulpitis Using Autologous
Dental Pulp Stem Cells & Leukocyte Platelet Rich Fibrin

7. Cell Therapy Application by Therapeutic Areas

7.1 Cardiovascular Disease

7.2 Neurological Disorders

7.3 Inflammatory Diseases

7.4 Diabetes

7.5 Cancer

8. Global Cell Therapy Market Outlook

8.1 Current Market Scenario

8.2 Cell Therapy Market by Cell Source

8.2.1 Induced Pluripotent Stem Cell (IPSCs)

8.2.2 Bone Marrow

8.2.3 Umbilical Cord Blood Derived Cells

8.3 Global Cell Therapy Clinical Pipeline (Company,Indication, Region)
Overview

9. US – Cell Therapy Dosage & Cost Analysis

9.1 Allocord

9.2 Laviv

9.3 Maci

9.4 Clevecord

9.5 Hemacord

9.6 Ducord

9.7 Provenge

9.8 HPC, Cord Blood (Clinimmune Labs, University of Colorado Cord Blood
Bank)

9.9 HPC, Cord Blood (LifeSouth Community Blood Centers, Inc)

9.10 HPC, Cord Blood (Bloodworks)

9.11 HPC, Cord Blood (MD Anderson Cord Blood Bank)

9.12 Gintuit

9.13 Kymriah*

9.14 Yescarta*

9.15 Carticel

10. South Korea – Cell Therapy Dosage & Cost Analysis

10.1 Cartistem

10.2 Chondron

10.3 KeraHeal

10.4 Cellgram

10.5 Cure Skin Injection

11. Australia, Europe & Japan – Cell Therapy Dosage & Cost
Analysis

11.1 Holoclar (Europe)

11.2 Yescarta (EU)

11.3 Kymriah (EU)

11.4 Temcell HS (Japan)

11.5 Chondrocytes-T-Ortho-ACI (Australia)

12. Cell Therapy Market Trends: Geographically

12.1 US

12.2 South Korea

12.3 Europe

12.4 Japan

12.5 China

12.6 Rest of the World

12.6.1 Africa

12.6.2 Middle East

12.6.3 South America

13. Advancements in Cell Therapy

13.1 Drug Based Therapies Advancements in Chronic Lymphocytic Leukemia

13.2 Advances in Cytomegalovirus Infection Prevention & Treatment

13.3 Stem Cell Therapy for the Treatment of Parkinson’s Disease

13.4 Stem Cell Therapy for the Treatment of Alzheimer’s Disease

13.5 Treatment of Rheumatoid Arthritis via Stem Cell Therapy

13.6 Role of Stem Cell Therapy in Treating Infertility

13.7 Stem Cells for Eye Diseases

13.8 Cell Therapy for Stroke and Angina Pectoris

13.9 Stem Cell Therapy in Improving Wrinkles & Acne Scars

14. Treg Cells – The Next Edge of Cell Therapy

14.1 Introduction to Treg Cell

14.2 Isolation & Expansion of Treg Cell

14.3 Mechanism of Action

14.4 Clinical Trials of Treg Cell Therapy

14.4.1 Adoptive Cell Therapy of Treg cells to Prevent GvHD

14.4.2 Adoptive Cell Therapy of Polyclonal & Alloantigen-specific Treg
cells to Prevent Solid Organ Transplant Rejection

14.5 Treg Cell Therapy for the Treatment of Autoinflammatory &
Autoimmune Diseases

14.5.1 Inflammatory Bowel Disease

14.5.2 Systemic Lupus Erythematosus

14.5.3 Autoimmune Hepatitis

14.5.4 Pemphigus Vulgaris

14.5.5 Allergy and Asthma

14.6 Future Prospects of Treg Cell Therapy

15. Global Cell Therapy Market Dynamics

15.1 Market Drivers

15.2 Commercial Challenges

16. Global Cell Therapy Market Future Prospects

17. Marketed Cell Therapies Clinical Insight by Company &
Indication

17.1 Tisagenlecleucel (Kymriah)

17.2 Axicabtagene Ciloleucel (Yescarta)

17.3 Allogeneic Cultured Keratinocytes And Fibroblasts (Gintuit)

17.4 Adipose Stem Cell Therapy (Adipocell (Anterogen), Cupistem &
Queencell)

17.5 Tonogenchoncel-L (INVOSSA-K inj)

17.6 Mesenchymal Stem Cell Therapies (Stempeucel)

17.7 Remestemcel-L (Prochymal & TEMCELL HS Inj.)

17.8 Sipuleucel-T (Provenge)

17.9 Autologous Mesenchymal Stem Cell Therapy – Pharmicell

17.10 Autologous Cultured Chondrocytes (MACI)

17.11 Autologous Cultured Chondrocytes (Chondrotransplant DISC)

17.12 Autologous Corneal Epithelial Stem Cell Therapy (Holoclar)

17.13 Nalotimagene Carmaleucel (Zalmoxis)

17.14 Mesenchymal Stem Cell Therapy For Cartilage Repair (Cartistem)

17.15 Autologous Chondrocyte Implant – TETEC

17.16 Muscle-Derived Autologous Stem Cell Therapy (MyoCell)

17.17 Human Skin Replacement (CellSpray)

17.18 Leukocyte Cell Therapy (CureXcell)

17.19 Autologous Cultured Chondrocyte Implant (Carticel)

17.20 Azficel-T (Laviv)

17.21 Autologous Cultured Chondrocytes (CHONDRON)

17.22 Autologous Chondrocytes (BioCart)

17.23 Amniotic Cell Therapy (NuCel)

17.24 Dendritic Cell-Activated Cytokine-Induced Killer Cells – Shanghai
Jia Fu Medical

17.25 Autologous Cultured Myoblasts And Fibroblasts (Urocell)

18. Global Cell Therapy Clinical Pipeline by Company, Indication
& Phase

18.1 Research

18.2 Preclinical

18.3 Clinical

18.4 Phase-0

18.5 Phase-I

18.6 Phase-I/II

18.7 Phase-II

18.8 Phase-II/III

18.9 Phase-III

18.10 Preregistration

18.11 Registered

19. Competitive Landscape

19.1 Athersys Inc.

19.2 Baxter Healthcare Corporation

19.3 Bone Therapeutics

19.4 Celgene Corporation

19.5 Cell Medica

19.6 Cellerant Therapeutics

19.7 FibrocellScinence

19.8 Genzyme Corporation

19.9 Green Cross Cell

19.10 Histogenics Corporation

19.11 Intrexon Corporation

19.12 Intercytex

19.13 ISTO Biologics

19.14 Macrocure

19.15 Mesoblast

19.16 Molmed

19.17 Nuo Therapeutics Inc

19.18 OmniCyte

19.19 Opexa Therapeutics

19.20 Organogenesis

19.21 Pharmicell

19.22 TCA Cellular Therapy

19.23 Stem Cell Inc.

19.24 Teva Pharmaceuticals

19.25 Tigenix

19.26 Vericel Corporation

For more information about this report visit https://www.researchandmarkets.com/r/d51vww

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Genomics,
Clinical
Trials